An Assessment of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Lifespan Distribution in Healthy Subjects
- 21 February 2007
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 24 (4) , 758-772
Abstract
An empirical pharmacodynamic model was developed to assess the effect of recombinant human erythropoietin (rHu-EPO) treatment on the reticulocyte production rate and lifespan distribution. Single doses of rHu-EPO at levels 20, 40, 60, 90, 120, and 160 kIU were administered to healthy volunteers (n = 8 per dose level). Erythropoietin plasma concentrations as well as hematologic responses were measured up to 42 days. The hematological data were used to determine explicit relationships between reticulocyte and red blood cell counts (RBC) and the reticulocytes’ production rate and lifespan distribution. The parameter estimates obtained by simultaneous fitting of the model to the reticulocyte and RBC data revealed that rHu-EPO transiently increased the reticulocyte lifespan from the baseline value of 1.7 days to 3.4 days and the effect lasted for 8.3 days. The dose dependent increase in the reticulocyte production had the maximal value of 77.5 109 cells/l/day and was followed by a rebound that was less than 9% of the baseline value. Both reticulocyte and RBC responses were preceded by a dose-independent lag time of 1.7 days. The effect of rHu-EPO on the reticulocyte production rate and lifespan distribution was characterized. The results of the present study can be further utilized in building more mechanistic pharmacodynamic models of rHu-EPO stimulatory effects.Keywords
This publication has 20 references indexed in Scilit:
- Pharmacodynamic Models for Agents that Alter Production of Natural Cells with Various Distributions of LifespansJournal of Pharmacokinetics and Pharmacodynamics, 2006
- Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjectsEuropean Journal of Pharmaceutical Sciences, 2005
- Pharmacodynamic Analysis of Changes in Reticulocyte Subtype Distribution in Phlebotomy-Induced Stress ErythropoiesisJournal of Pharmacokinetics and Pharmacodynamics, 2005
- Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy VolunteersThe Journal of Clinical Pharmacology, 2004
- The impact of timing of chemotherapy relative to darbepoetin alfa (DA) on DA pharmacokinetics (PK) and hematologic effectsClinical Pharmacology & Therapeutics, 2004
- Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Dose Administration in Cynomolgus MonkeysThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects*Clinical Pharmacology & Therapeutics, 1998
- rh‐Erythropoietin stimulates immature reticulocyte release in manBritish Journal of Haematology, 1994
- A mathematical model of erythropoiesis in mice and rats Part 1: Structure of the modelCell Proliferation, 1989
- Maturation of the MacroreticulocyteBritish Journal of Haematology, 1969